AU5109400A - Therapeutic compositions for ophthalmic use and therapeutic compositions for brain central lesions - Google Patents

Therapeutic compositions for ophthalmic use and therapeutic compositions for brain central lesions

Info

Publication number
AU5109400A
AU5109400A AU51094/00A AU5109400A AU5109400A AU 5109400 A AU5109400 A AU 5109400A AU 51094/00 A AU51094/00 A AU 51094/00A AU 5109400 A AU5109400 A AU 5109400A AU 5109400 A AU5109400 A AU 5109400A
Authority
AU
Australia
Prior art keywords
therapeutic compositions
ophthalmic use
brain central
central lesions
lesions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU51094/00A
Inventor
Kentaro Okamoto
Shinseiro Okamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Medicine Research Institute
Original Assignee
Advanced Medicine Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Research Institute filed Critical Advanced Medicine Research Institute
Publication of AU5109400A publication Critical patent/AU5109400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU51094/00A 1999-06-14 2000-06-13 Therapeutic compositions for ophthalmic use and therapeutic compositions for brain central lesions Abandoned AU5109400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11/166784 1999-06-14
JP16678499 1999-06-14
PCT/JP2000/003830 WO2000076454A2 (en) 1999-06-14 2000-06-13 Therapeutic compositions for ophthalmic use and therapeutic compositions for brain central lesions

Publications (1)

Publication Number Publication Date
AU5109400A true AU5109400A (en) 2001-01-02

Family

ID=15837622

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51094/00A Abandoned AU5109400A (en) 1999-06-14 2000-06-13 Therapeutic compositions for ophthalmic use and therapeutic compositions for brain central lesions

Country Status (2)

Country Link
AU (1) AU5109400A (en)
WO (1) WO2000076454A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040839A1 (en) * 2004-10-15 2006-04-20 Advanced Medicine Research Institute Eye drops and kit for treatment of eye disease
AU2008271911B2 (en) * 2007-06-29 2014-08-07 Phovitreal Pty Ltd Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration
CN110678753B (en) 2017-03-30 2023-10-24 普莱戈斯瑞恩癌症有限责任公司 Compositions and methods for treating lung cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443432A (en) * 1981-10-05 1984-04-17 Alcon Laboratories, Inc. Ophthmalic irrigating solution
JPH0643338B2 (en) * 1988-08-05 1994-06-08 参天製薬株式会社 Anti-cataract eye drops
JPH0611704B2 (en) * 1989-01-19 1994-02-16 参天製薬株式会社 Eye drops for corneal disease treatment
US5281353A (en) * 1991-04-24 1994-01-25 Allergan, Inc. Compositions and methods for disinfecting/cleaning of lenses and for destroying oxidative disinfectants
US5328701A (en) * 1992-09-10 1994-07-12 Peregrine Surgical Ltd. Tissue irrigation solution
JPH0848634A (en) * 1994-08-05 1996-02-20 Akio Okamoto Cornea-treating agent
WO1998010785A1 (en) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
JPH10218787A (en) * 1997-02-06 1998-08-18 Akio Okamoto Ophthalmic composition based on neurotrophic factor

Also Published As

Publication number Publication date
WO2000076454A2 (en) 2000-12-21
WO2000076454A3 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
AU6489600A (en) Patient monitor
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU3365401A (en) Use of ketotifen as ophthalmic agent
AU1164601A (en) Therapeutic use and formulation
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU5215300A (en) Dental treatment area
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
HUP0104963A3 (en) Compositions for the treatment of skin diseases
AU4511201A (en) Compositions and methods for the induction and treatment of retinal detachments
AU2451500A (en) Therapeutic agents
AU7106300A (en) Treatment of skin disorders
AU3978700A (en) Medical use
AU7280200A (en) Seed dressing agent formulations
AU1878201A (en) Composition for the treatment of damaged tissue
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU5109400A (en) Therapeutic compositions for ophthalmic use and therapeutic compositions for brain central lesions
AU5973600A (en) Therapeutic agents
EP0878200A4 (en) Therapeutic agent for ophthalmic diseases
AU1022501A (en) Use of compositions for the caring treatment of the skin
AU1043601A (en) Medical use
AU2683500A (en) Compositions for the treatment of pain
AU2001228863A1 (en) Remedies for ophthalmic diseases
AU2136500A (en) Preparation for dental treatment
AU3190595A (en) Corneal therapeutic agent
AU5759500A (en) Methods for ameliorating icthyosiform skin diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase